^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BTN2A1-H

    i
    Other names: BTN2A1, Butyrophilin Subfamily 2 Member A1, BT2.1, BTF1, Butyrophilin Subfamily 2 Member A1, BK14H9.1, DJ3E1.1, BTN2.1
    Entrez ID:
    11120
    over3years
    Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma. (PubMed, Front Immunol)
    Our results suggest that the baseline level of plasmatic BTN2A1 could be an independent prognosis factor of PFS after nivolumab for pre-treated patient with mRCC. However, these results need to be validated in a larger prospective cohort and the biological role of BTN subfamily and γδ T cell immunity in mRCC must be elucidated.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • BTLA (B And T Lymphocyte Associated) • BTN2A1 (Butyrophilin Subfamily 2 Member A1) • BTN3A1 (Butyrophilin Subfamily 3 Member A1)
    |
    BTN2A1-H
    |
    Opdivo (nivolumab)
    over4years
    [VIRTUAL] Soluble BTN2A1 as a potential predictive biomarker of immune checkpoint inhibitor efficacy in advanced non-small cell lung cancer (NSCLC). (ASCO 2020)
    The confirmation cohort (Paoli-Calmettes Institute) included 42 patients treated with ICI (nivolumab or pembrolizumab) in a longitudinal prospective setting (Immunosup trial, NCT03595813). In advanced NSCLC patients, a high baseline plasmatic concentration of soluble BTN2A1 was correlated with improved outcomes for ICI, but not for chemotherapy, suggesting that baseline soluble BTN2A1 level is a potential predictive biomarker of ICI efficacy. Additional studies are ongoing to confirm this finding. Research Funding: Institut Paoli Calmettes and Rennes University Hospital
    Clinical • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • BTN2A1 (Butyrophilin Subfamily 2 Member A1)
    |
    BTN2A1-H
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)